Mucous membrane pemphigoid encompasses a group of autoimmune bullous diseases with a similar phenotype characterized by subepithelial blisters, erosions, and scarring of mucous membranes, skin, or both. Although knowledge about autoimmune bullous disease is increasing, there is often a lack of clear definitions of disease, outcome measures, and therapeutic end points. With clearer definitions and outcome measures, it is possible to directly compare the results and data from various studies using meta-analyses. This consensus statement provides accurate and reproducible definitions for disease extent, activity, 
outcome measures, end points, and therapeutic response for mucous membrane pemphigoid and proposes a disease extent score, the Mucous Membrane Pemphigoid Disease Area Index. ( J Am Acad Dermatol 2015;72:168-74.)
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BACKGROUND
Mucous membrane pemphigoid (MMP) encompasses a group of autoimmune bullous diseases with a similar phenotype characterized by subepithelial blisters, erosions, and scarring of mucous membranes, skin, or both. It is associated with high morbidity and mortality, and without treatment patients can develop esophageal and laryngeal stenosis, strictures, and blindness. 1 Given the severe potential complications of MMP, effective treatment is required to delay and halt progression. Because of the rarity of this condition, however, large randomized controlled trials are lacking, and the evidence supporting these therapies is limited. 2 There has been an excellent consensus on the diagnosis of MMP, 1 but there exists a lack of clear definitions of disease stages, outcome measures, and therapeutic end points. With clearer definitions and outcome measures for MMP, it will be possible to directly compare the results and data from various studies using meta-analysis. Although ophthalmologists already developed a number of scoring systems for ocular MMP, a problem with these scores is that they combine activity with damage and are too complex for dermatologists to use. It was therefore also our intention to develop and propose a scoring system for MMP that would be practical for dermatologists who see these patients regularly to use to monitor response to therapy, which separated reversible activity from damage.
PURPOSE
The purpose of this consensus statement is to provide accurate and reproducible definitions for disease extent, activity, outcome measures, end points, and therapeutic response for MMP. Using the same definitions of response and end points allows direct comparison of clinical trials and facilitates the analysis of these results in systematic reviews. J AM ACAD DERMATOL VOLUME 72, NUMBER 1 disease were invited to participate in the development of the MMP definitions. Experts in the field and those who had participated in previous consensus statements on pemphigus and bullous pemphigoid were invited. 3, 4 The committee convened 8 times over 2 years to discuss and develop appropriate definitions. . At each meeting, the minutes and issues at the previous meetings were discussed until a consensus on the definitions was made. The draft definitions and manuscript were electronically mailed to the entire committee for comments and discussion. The final consensus is the product of many meetings, discussions, and agreement. There is universal agreement in the committee about the definitions of end points, therapeutic responses, and treatment failures along with a score, termed ''Mucous Membrane Pemphigoid Disease Area Index'' (MMPDAI), for milder forms of MMP. For this method, the committee reviewed photographic examples from the group of patients with MMP, in particular the eyes and mouth, to discuss which areas to give weight to in the MMPDAI compared with the previous Bullous Pemphigoid Disease Area Index (BPDAI). It was decided to expand the score for the eyes to include both the left and right eye separately, which would give the eyes a weighting of 2 of 12 rather than 1 of 12 and to combine the tongue and floor of mouth as they are less often separately affected than other areas in the mouth. To further expand the weighting of the eyes, it was decided to use the quadrant system, as for the scalp, rather than counting individual lesions, which are difficult for dermatologists to visualize without a slit lamp. Because dermatologists typically cannot accurately assess other elements of the eyes, and the nasal, laryngeal, and esophageal mucosae, severe forms of MMP that may cause significant damage to these areas will require their own more detailed scores to evaluate each of these in a more specific manner.
CONSENSUS METHODS

THE CONSENSUS Observation points
The end points are summarized in Table I .
Early observation end points ''Baseline'' is defined as the day that MMP therapy is started by a physician.
''Control of disease activity'' is defined as the time at which new inflammatory lesions cease to form and established lesions begin to heal. ''Time to control of disease activity'' (disease control; beginning of consolidation phase) is the time interval from baseline to the control of disease activity.
''Control of scarring'' is defined as the time needed to control scarring progression.
''End of consolidation phase'' is defined as the time at which no new lesions have developed for a minimum of 4 weeks and lesions and approximately 80% of inflammatory lesions have healed.
Intermediate observation end points
''Transient lesions'' are new lesions that heal within 1 week or clear without treatment. ''Nontransient lesions,'' however, are new lesions that do not heal within 1 week.
''Complete remission during tapering'' is the absence of nontransient lesions while the patient is receiving more than minimal therapy.
''Long-term biologic therapy'' refers to therapies given intermittently, for example, when rituximab is used for MMP, or intravenous immunoglobulin monthly. ''Ongoing biologic therapy'' is characterized by the use of drugs such as rituximab.
Late observation end points of disease activity are identified as: (1) partial remission on minimal therapy; (2) complete remission on minimal therapy; Pemphigus Disease Area Index (3) partial remission off therapy; and (4) complete remission off therapy. ''Partial remission on minimal therapy'' is the presence of transient new lesions that heal without scarring within 1 week while the patient is receiving minimal therapy for at least 2 months. ''Complete remission on minimal therapy'' is the absence of new or established lesions while the patient is receiving minimal therapy for at least 2 months. ''Partial remission off therapy'' is the presence of transient new lesions that heal within 1 week without treatment while the patient is off all MMP therapy for at least 2 months. ''Complete remission off therapy'' is the absence of new or established lesions while the patient is off all MMP therapy for at least 2 months.
MMP Disease Activity Index
Like the Pemphigus Disease Area Index (PDAI) and BPDAI, 3,4 the MMPDAI (Table II) measures 4, 6 These tools have in common that about 45% of the score reflects skin involvement, 45% mucosal involvement, and 10% the scalp, measured in a different way to the rest of the skin. Each score has different weightings placed on the sites involved that reflect the propensity for those areas to be affected in that particular blistering disease, so that severities can be more easily distinguished, and for responsiveness to treatment to be measurable. In each condition, scarring sequelae (referred to as ''damage'') are scored separately from reversible disease activity and the two should not be combined.
The MMPDAI is applicable for milder forms of MMP. This tool is primarily for dermatologists who specialize in blistering diseases and who see patients with MMP regularly, but can also be used by other members of a multidisciplinary team for patients with MMP. The main purpose is its use in clinical studies for intervention and evaluation in MMP. It includes 2 columns, namely activity and damage, to separate active erosions and blisters from postinflammatory changes and scarring from resolving lesions. Active lesions are evaluated in each eye that have been divided into 4 distinct quadrants and airway scores (Fig 1) elicited depending on upper airway or posterior pharyngeal involvement. Other anatomic locations commonly affected by MMP were taken into consideration so that this score could differentiate between clinical responses in MMP. Some of the notable differences between BPDAI and MMPDAI include the addition of scarring to column ''damage''; involvement of the forehead and shoulders, combination of legs and feet; and separation of anal, genital, and buttock involvement. Most notably, however, there is a separate section for scalp involvement and greater weight is given to the various mucosal surfaces. As the Brunsting-Perry form of MMP often includes the scalp and causes scarring alopecia, and this area of the body is difficult to conceal compared with other skin areas covered with clothing, it is more cosmetically disfiguring for patients. Hence, up to about 5% of the total score may be given for total scalp involvement.
Other activity scores for MMP or lichen planus with laryngeal lesions, esophageal lesions, and/or ocular fibrosis were evaluated for clinical relevance and ease of use. [7] [8] [9] Precisely scoring the ocular and laryngeal involvement would be ideal for monitoring and making therapeutic decisions. However, this excess detail had to be balanced with ease of completion in clinical and research settings for dermatologists and whether such detail would provide additional beneficial information to clinical decision making is currently uncertain. The MMPDAI will undergo validation studies, similar to the PDAI and BPDAI.
DISCUSSION AND CONCLUSION
Because of the rarity and heterogeneity of MMP and paucity of randomized controlled trials, it has been difficult to compare the various proposed therapeutic options for MMP. This consensus paper with definitions of disease and response represents extensive discussion and agreement among experts of MMP. It provides a foundation for researchers and clinicians to develop studies with agreed upon end points so that results can be directly compared. It also provides a framework for other specialties such as ophthalmology and otolaryngology to develop a similar accurate scoring system to stage and measure the progress of MMP. J AM ACAD DERMATOL VOLUME 72, NUMBER 1
